Fonte: Il Messaggero
Let’s start testing on the “tricolour” vaccine, but not in Italy
Anglo-Italian vaccine. The OK of the experts has arrived: “The premises are excellent, this vaccine is the closest to the cure”
Favourable opinion of Italian Istituto Superiore di Sanità. Rezza defines it “a promising research”. First clinical trials on 550 volunteers. Short time possible as the side effects are indirectly known. Adenovirus and the results on Ebola and Sars are being used.
Giovanni Rezza, Head of Infectious Diseases Department at ISS, confirms his interest in the study on Sars Cov 2, which involves a partnership between the Jenner Institute of Oxford University and Advent, the cGMP-certified Contract Development and Manufacturing Organization of IRBM Group, located in Pomezia (Rome). This study could achieve the goal before the others, as “it utilizes – Rezza explains – a platform already employed for studies on Ebola and other virus”. It could be possible to move forward quickly, as side effects are already known, while they are often an obstacle to a vaccine manufacturing. We all wonder when one or more vaccines could be ready. With regard to the Jenner Institute/Advent study, Rezza believes that it may arrive in fast times, within this year, even if he prefers not to hazard an exact date. We could return to a “normal” life thanks to the vaccine only. “Phase 2 is not started yet in Italy – Rezza warns – we have to get used with the idea of wearing masks, keeping safe distance and washing our hands frequently”.
Article by Francesca Angeli published on il Giornale – 14/04/2020